Related Experiment Video

Updated: Jan 17, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

SNORA33 Promotes Clear Cell Renal Cell Carcinoma Development and Resistance to Sunitinib Through Triggering the

Jiajia Sun1, Shuo Zhao1, Xiaochen Ren1

  • 1Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China.

IUBMB Life
|September 24, 2025
PubMed

Insights

SNORA33 is highly expressed in clear cell renal cell carcinoma (ccRCC), promoting tumor progression and sunitinib resistance. This small nucleolar RNA (snoRNA) may serve as a biomarker for ccRCC immunotherapy prediction.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Small nucleolar RNAs (snoRNAs) play roles in various cancers.
  • The specific function of SNORA33 in clear cell renal cell carcinoma (ccRCC) is not well understood.

Purpose of the Study:

  • To investigate the role and mechanism of SNORA33 in ccRCC tumorigenesis and progression.
  • To evaluate SNORA33 as a potential biomarker for ccRCC immunotherapy.

Main Methods:

  • Analysis of snoRNA expression data from TCGA and SNORic databases.
  • Kaplan-Meier analysis and Cox regression for prognostic value.
  • In vitro experiments to assess SNORA33 function in ccRCC cells.
  • Gene set enrichment analysis (GSEA) and western blot to explore mechanisms.

Main Results:

  • SNORA33 is highly expressed in ccRCC and associated with poor prognosis.
  • SNORA33 correlates with immune cell infiltration, immune score, and immune checkpoint molecules.
  • In vitro studies show SNORA33 promotes ccRCC proliferation, invasion, migration, and sunitinib resistance.
  • SNORA33 mediates the JAK/STAT pathway in ccRCC progression.

Conclusions:

  • SNORA33 is a key driver in ccRCC progression, invasion, metastasis, and drug resistance.
  • SNORA33 serves as a potential biomarker for predicting immunotherapy response in ccRCC patients.
  • Targeting SNORA33 or the JAK/STAT pathway may offer therapeutic strategies for ccRCC.
Keywords:
SNORA33clear cell renal cell carcinomajak/stat pathwaysunitinib

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

719
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.3K